Vasonorm

Quick links to important sections

Vasonorm

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasonorm

What is Vasonorm? (Identity and Classification)

Property Description
Active Ingredient Amlodipine
Form Oral Tablet
Pharmacological Class Calcium Channel Blocker (CCB), Dihydropyridine
Common Therapeutic Purpose Antihypertensive and Antianginal Agent
Origin Synthetic

The identity of Vasonorm, in the context of an Amlodipine-based preparation, is rooted in its highly selective cardiovascular action. It is definitively categorized as a long-acting Calcium Channel Blocker (CCB), placing it within the dihydropyridine subset of cardiovascular agents.

What is the Composition and Type of Vasonorm?

Vasonorm is a monotherapy containing the synthetic active ingredient Amlodipine, which is often complexed as the Amlodipine besilate salt. This specific besilate salt formulation is clinically recognized for its predictable drug delivery. The drug belongs to the dihydropyridine subset, which is distinguished from other CCBs by its primary action on the peripheral vasculature rather than the heart’s conduction tissue. The unique long-acting chemical profile of Amlodipine ensures consistent therapeutic effects over a 24-hour period, a property central to its clinical utility for chronic management.

In What Form is Vasonorm Supplied?

The preparation is supplied to patients as an oral tablet for oral administration. This particular dosage form is designed to accommodate Amlodipine's long half-life, promoting the necessary sustained release for once-daily use. The general therapeutic purpose of Vasonorm is directed toward systemic blood pressure reduction and the management of chronic stable chest pain, achieving this goal by mediating peripheral arterial vasodilation to ease the heart's workload.

What side effects are possible with Vasonorm?

Possible Side Effects and Safety Information

The safety profile of Vasonorm, which contains the active ingredient Amlodipine, is based on classifications from governmental regulatory sources, such as the EMA and FDA, which define the probability and type of adverse reactions.


Frequency and System-Organ Classifications

The most frequently reported side effects are categorized by regulatory agencies based on incidence:

  • Very Common (ge 1/10): Oedema (swelling, typically of the ankles), which is often dose-related.
  • Common (ge 1/100 to <1/10): Headache, dizziness, fatigue, nausea, abdominal pain, and flushing. These effects, particularly headache and dizziness, are noted in the regulatory text to occur especially at the beginning of the treatment.

Adverse reactions are formally grouped into System-Organ Classes (SOC), covering areas like Vascular Disorders (flushing), Nervous System Disorders (somnolence), and Cardiac Disorders (palpitations).


Serious Reactions and Safety Considerations

Serious adverse reactions are those rare but clinically significant events documented in official labeling. These include very rare reports of severe dermatological reactions ( e.g., Stevens-Johnson syndrome and angioedema) and hepatic dysfunction, such as jaundice and hepatitis. A risk of worsening angina or acute myocardial infarction can develop in high-risk patients after starting or increasing the dose.

Population-specific safety statements advise caution for older adults and patients with hepatic impairment due to altered clearance of the medicine. The medication is contraindicated in certain critical conditions, including severe hypotension and cardiogenic shock.

Overdose and Emergency Response

The official regulatory documentation defines Vasonorm (Amlodipine) overdose by its potential for severe, life-threatening cardiovascular manifestations. The primary presentation involves prolonged marked hypotension resulting from excessive peripheral vasodilation, which may become refractory to initial treatment. Overdose may also be associated with heart rate changes, including tachycardia or bradycardia. Severe systemic outcomes documented in official reports include shock, acute renal failure, multiple organ failure, and death.

Due to the recognized severity and the long half-life of the drug, regulatory authorities mandate urgent action. Seek immediate medical attention for any suspected overdose. It is required to contact emergency services or a Poison Control Center immediately, even if the person is asymptomatic, as severe complications can be delayed. Urgent help is especially required if the person has collapsed, experienced a seizure, or has breathing difficulties.

Management, as described in regulatory labels, emphasizes symptomatic and supportive treatment, as no specific antidote is known. Procedural steps include initial administration of intravenous fluids and may progress to the use of vasopressors and calcium administration to counteract cardiovascular effects. Extended hospital monitoring is required for all ingestions, particularly due to the long-acting nature of the drug, to observe for late-onset toxicity.

Therapeutic Uses of Vasonorm

Vasonorm: Main Uses and Benefits

Quick Facts

  • Primary Use: Management of high blood pressure (hypertension).
  • Cardiovascular: Helps manage heart failure and may be used after a heart attack to support cardiac function.
  • Risk Reduction: Aids in reducing the probability of serious cardiovascular events, such as a heart attack or stroke.

Vasonorm is prescribed by qualified medical professionals primarily for the management of high blood pressure, a clinical condition often referred to as hypertension. Maintaining blood pressure at appropriate levels helps to decrease the work required by the heart and supports the health of the cardiovascular system.

The medication is also utilized in the comprehensive management of heart failure, where it helps to manage symptoms and supports the heart's function in circulating blood. In patients who have experienced a heart attack, Vasonorm may be part of the long-term treatment plan to support cardiac recovery. By assisting with blood pressure control, the therapy contributes to a reduction in the risk of serious health complications, including stroke and heart attack.

This medication may be used alone or in combination with other therapeutic agents, such as diuretics. The active component of Vasonorm is enalapril maleate.

Eligibility and Restrictions for Use

Vasonorm is an Amlodipine-based medicine whose eligibility for use is defined by strict regulatory criteria based on age, pre-existing conditions, and physiological status.

Contraindications and Non-Eligibility

Vasonorm is contraindicated (must not be used) for patients with a known hypersensitivity to Amlodipine, other dihydropyridine derivatives, or any excipients in the tablet. Use is also formally prohibited in the presence of specific acute cardiovascular states, including severe hypotension, cardiogenic shock, and significant aortic stenosis.

Age-Related Eligibility

Age Group Eligibility Status (Regulatory Basis)
Adults (18+ years) Approved for all primary indications.
Children (6–17 years) Approved for hypertension only.
Children (Under 6 years) Safety and efficacy have not been established.
Older Adults (Geriatric) Use is permitted; however, cautious dose titration is required due to potential changes in function.

Condition-Based Restrictions

Use is restricted or conditional for certain patient populations:

  • Hepatic Impairment: Patients with liver function impairment require caution, as the body processes the medicine slower. Use in severe hepatic impairment is generally not recommended.
  • Renal Impairment: No dosage adjustment is typically required, as renal impairment does not significantly alter the drug's concentration.
  • Pregnancy and Lactation: Use during pregnancy is generally not recommended unless there is no safer alternative. Breastfeeding should be discontinued during therapy, as Amlodipine is excreted in human milk.

Official regulatory documents define these eligibility rules to ensure the medicine is used only by approved populations under defined conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The active ingredient in Vasonorm, Amlodipine, has officially documented interaction patterns primarily based on its metabolic pathway and pharmacodynamic effects. The concurrent use of strong or moderate CYP3A inhibitors (such as certain antifungals) results in a pharmacokinetic interaction that increases Amlodipine's systemic exposure. Conversely, CYP3A inducers (like rifampin) may decrease its plasma concentration.


The regulatory profile requires a critical interaction-related restriction concerning co-administered Simvastatin. Amlodipine significantly increases Simvastatin exposure, and the maximum daily dose of Simvastatin must be limited to 20 mg. Amlodipine also increases the exposure of the immunosuppressants Cyclosporine and Tacrolimus.


Formal restrictions include that Amlodipine is contraindicated with intravenous Dantrolene. Pharmacodynamic interactions include additive blood pressure lowering when Vasonorm is combined with other antihypertensive agents or alcohol. In terms of substance interactions, grapefruit or grapefruit juice may increase Amlodipine's plasma levels, though the presence of food does not alter its overall bioavailability. A population-specific note highlights that patients with hepatic impairment exhibit reduced clearance and a prolonged half-life, resulting in increased exposure.

Mechanism of Action

Selective Blockade of Vascular Calcium Channels

Vasonorm acts within specific pharmacodynamic domains, influencing the circulatory system by focusing entirely on molecular targets and their physiological cascades. The core mechanism involves acting as an inhibitor of L-type voltage-dependent calcium channels ( CaV1.2), which are critical signaling units in vascular smooth muscle membranes. By preferentially blocking these channels, Vasonorm prevents the necessary influx of extracellular calcium ions ( Ca^2+) into the muscle cells, which is the essential trigger for contraction.


Modulation of Arterial Tone and Systemic Resistance

Interrupting the calcium influx directly inhibits the activation of the cellular contractile machinery (actin-myosin cross-bridging), leading to a state of relaxation in the arterial walls (peripheral arterial vasodilation). This physiological change causes a fundamental drop in the overall resistance against which the heart must pump—known as Total Peripheral Resistance (TPR).


Reduction of Myocardial Workload (Afterload)

The systemic reduction in TPR directly lessens the physical force opposing the heart's blood ejection (afterload). This reduction is the resulting physiological effect, as it decreases the workload on the myocardium, consequently lowering the heart's oxygen demand and contributing to a change in circulatory dynamics.

Dosage and Administration Information

How to Use Vasonorm

The usage of Vasonorm, an amlodipine-based product, is determined by standardized administration protocols designed for chronic management. The therapy is delivered solely via the oral route as a tablet.


Official Administration Guidelines

Feature Official Instruction
Route of Administration Oral
Dosing Schedule (Adult) Standard starting dose is 5 mg once daily; the maximum daily dose is 10 mg.
Frequency and Timing Taken once daily at approximately the same time each day. May be taken with or without food.
Titration Interval Dosage adjustments, when required, should generally proceed slowly over 7 to 14 days to fully assess the patient's response.

Population-Specific Dosing Principles

Established guidelines identify specific populations that may require a reduced starting dose. A low initial dose of 2.5 mg once daily is suggested for small or fragile patients, older adults, and individuals with hepatic impairment. For pediatric patients aged 6 to 17 years being treated for hypertension, the effective oral dose ranges from 2.5 mg to 5 mg once daily, with doses exceeding 5 mg per day not having been studied in this age group.

In the event of a missed dose, the standard procedure is to take the dose as soon as it is remembered on that day. However, if it is almost time for the next scheduled dose, the missed dose must be skipped entirely, and the patient must never take a double dose to compensate. This procedural structure ensures the long-acting daily regimen is maintained consistently.

Recent Clinical Evidence

Research evidence / Overview of Studies for Vasonorm


Evidence for Use in High Blood Pressure (Hypertension)

Research exploring Vasonorm for high blood pressure was primarily conducted using large-scale RCTs. These studies, some lasting several years, compared the effects of Vasonorm (Amlodipine) against a placebo or against other established types of blood pressure medications. Researchers examined outcomes related to systemic imbalance by measuring changes in both systolic and diastolic blood pressure over defined time intervals. These major trials also monitored the incidence of serious episodic changes, including non-fatal heart attacks and strokes, in the observed populations.

The studies reported measurements of changes in blood pressure and described the patterns observed during the study period. The long-term trials monitored the occurrence of fatal and non-fatal cardiovascular events over follow-up periods lasting several years. Findings describe group patterns related to the overall occurrence of events like stroke, and these findings contribute to the broader evidence landscape regarding outcomes over long periods compared to those on other treatments.

Research has explored Amlodipine in the treatment of high blood pressure, but long-term outcomes for certain groups are not fully established. For example, while one large trial described patterns related to event rates, differences in outcomes were observed when compared to a diuretic-based regimen. Furthermore, data for the very long-term effects in pediatric patients remains insufficient, as the primary trials focused on adults.


Evidence for Use in Coronary Artery Disease and Angina

Vasonorm was evaluated in several studies for patients with stable chest pain, known as chronic stable angina, and in those with coronary artery disease (CAD). The initial research explored short-term symptom changes, often using placebo-controlled, double-blind RCTs. These trials examined outcomes related to physical discomfort by recording how often patients experienced chest pain episodes. They also monitored functional measures, such as how long patients could exercise before symptoms appeared.

Studies focusing on stable angina reported how symptoms evolved in the observed populations, with findings describing patterns related to the frequency of angina episodes. Research conducted on patients with documented CAD, even without severe heart failure, monitored the occurrence of certain cardiac procedures. These long-term studies observed responses over defined time intervals, and the findings contribute to the broader evidence landscape regarding the need for procedures like coronary revascularization.

Research exploring short-term symptom changes described the patterns observed in the studies, which were generally consistent across the trials. However, the existing studies provide limited information for long-term outcomes related to procedural risk reduction in all possible subgroups of CAD patients. The specific study criteria often excluded patients with more severe co-existing conditions, meaning the results apply only to the populations studied.


Evidence in Special Populations and Comorbidities

Research has also explored the use of Amlodipine in specific populations. Trials evaluating the treatment of high blood pressure have included a significant number of older adults, helping to describe the patterns observed in this age group.

For children and adolescents (aged 6 to 17 years), Vasonorm was studied for high blood pressure in short-term randomized trials. These studies examined outcomes related to systemic or functional imbalance by monitoring the change in blood pressure compared to a placebo. The findings describe group patterns, and research suggests Amlodipine was studied for high blood pressure in this population. However, long-term effects are not fully established, and there is limited information for outcomes beyond one year in this age group.

Vasonorm was evaluated in patients with a range of comorbidities, including diabetes and high cholesterol, as these patients often participate in the large cardiovascular outcomes trials. Research describes the patterns observed in patients with these conditions associated with acute or disruptive episodes, contributing to the overall evidence landscape.


Long-Term Research and Durability of Study Findings

The most informative evidence regarding the observed patterns comes from large-scale, long-term RCTs that monitored patients for cardiovascular outcomes for up to four to six years. These studies are critical because they allow researchers to observe responses over defined time intervals that extend beyond a few months.

The reported findings describe patterns observed in the studies and provide insight into the long-term changes related to blood pressure control and the occurrence of major cardiovascular events over extended periods. For high blood pressure, the duration of follow-up in these trials involves the monitoring of outcomes linked to physiological strain or stress over many years.

However, the evidence quality varies across studies. While some trials described sustained patterns, data for certain groups remain insufficient. For instance, some of the specific research focusing only on special populations, such as children, has follow-up durations that were limited, making the assessment of long-term patterns in those groups incomplete.


Areas of Research Uncertainty and Inconsistency

Despite a large body of evidence, certain areas of research remain uncertain. Research involving patients with severe chronic heart failure provides a notable example of inconsistent findings. Two large-scale survival studies explored the effects of Amlodipine in addition to standard heart failure treatment, and their reported results tracking outcomes like mortality were mixed. Because of these inconsistent findings, the overall evidence for use in the general heart failure population remains limited.

Furthermore, although Vasonorm was studied for high blood pressure in children aged 6 and older, data for certain groups remain insufficient, particularly for patients younger than six years old, where effectiveness is not fully established. For all age groups, comparative evidence involving Vasonorm versus other specific blood pressure treatments may be lacking in some specialized scenarios. These limitations evidence highlights what is known — and what is still uncertain about this medicine.

Frequently Asked Questions (FAQ)

Common questions about Vasonorm (FAQ)

Q: How quickly should I expect to see an effect from Vasonorm?

A: Vasonorm is described in official product information as a long-acting medicine. The concentration in the blood reaches its peak between 6 and 12 hours after taking the dose, and the blood pressure-lowering effect is designed to last for at least 24 hours. However, the medicine must build up in the body, and the full steady-state level is generally achieved after approximately 7 to 8 days of taking it consistently every day.


Q: Can older adults use Vasonorm safely?

A: Official documents confirm that Vasonorm has been studied in and is permitted for use in older adults. However, regulatory guidance notes that this population may exhibit altered clearance of the medicine. Due to potential changes in function, cautious dose titration (adjustment) is required.


Q: Is the tiredness I feel from Vasonorm a common side effect?

A: Official reports from regulatory agencies list fatigue, or tiredness, as a common side effect. This means it is reported in between 1 in 100 and 1 in 10 patients in clinical trials. This effect is specifically noted in official documents to occur especially when treatment is first started.


Q: Does Vasonorm have a specific time of day it should be taken?

A: No, official guidelines state that Vasonorm may be taken at any time of day, and it can be taken with or without food. The main instruction is that the medicine should be taken once daily at approximately the same time each day to help maintain consistent levels of the medicine in the body.


Q: What is meant by the 'safety classification' of Vasonorm?

A: The safety classification refers to the regulatory method of organizing adverse events reported during clinical trials. Effects are categorized based on how often they occurred in the studied population, such as Very Common (occurring in 1 in 10 people or more) or Common (occurring in 1 in 100 to less than 1 in 10 people). This helps define the expected frequency of different effects.


Q: Can Vasonorm be crushed and mixed with food or liquid?

A: Vasonorm is supplied as an oral tablet. Official administration documents do not typically authorize altering the tablet by crushing or splitting, unless the tablet is officially scored. Therefore, the physical alteration of the tablet's form is not established in the official labeling.


Q: Does Vasonorm affect cholesterol levels?

A: Official documents focus on the medicine's interactions with other drugs, particularly cholesterol-lowering medicines like Simvastatin. Regulatory guidance requires limiting the Simvastatin dose when taken with Vasonorm. This highlights an interaction related to how Vasonorm affects Simvastatin's metabolism, but it does not indicate that Vasonorm independently alters cholesterol levels in the body.


Q: Is Vasonorm an ACE inhibitor or a beta-blocker?

A: No. Official documents define Vasonorm as a Calcium Channel Blocker (CCB), which belongs to a class of medicines called dihydropyridines. ACE inhibitors and beta-blockers are different drug classes that work through different mechanisms in the body.


Q: What happens if a child accidentally takes Vasonorm?

A: Official safety instructions strictly state that Vasonorm must be stored out of the sight and reach of children. The active ingredient can cause serious effects, such as severe low blood pressure. Authoritative medical resources indicate that accidental ingestion requires prompt evaluation by a healthcare provider.


Q: Are there specific dietary restrictions while on Vasonorm?

A: Official regulatory documents specifically note that the consumption of grapefruit or grapefruit juice may increase the amount of medicine in the blood. No other specific food-based dietary restrictions are typically noted in the official prescribing information beyond this interaction.


Q: Are there known interactions between Vasonorm and herbal remedies?

A: Regulatory guidance recommends informing a healthcare provider about all medicines, including herbal remedies, as these are not typically studied with Vasonorm in the same way as prescription drugs. Patient information leaflets sometimes note that certain herbal remedies, like St. John’s Wort, may have the potential to alter the medicine's activity.


Q: How is the safety of Vasonorm monitored after it is released to the public?

A: The safety of Vasonorm is continuously monitored by regulatory bodies after its approval and release. This process is called post-marketing surveillance. It involves the ongoing collection and analysis of reports on any adverse events that occur during the medicine's general use by the public.


Q: What happens if Vasonorm is taken for a condition it is not approved for?

A: Official regulatory documents define the specific conditions for which Vasonorm is indicated (approved). Use of the medicine for any condition that is not listed in the official indications section is outside the scope of its defined regulatory approval.


Q: Is Vasonorm addictive?

A: Vasonorm is not classified as a controlled substance by regulatory agencies such as the FDA. Official drug classifications do not associate this medicine with the potential for abuse or dependence.


Q: How is Vasonorm different from other similar medicines?

A: Vasonorm is primarily distinguished by its classification as a long-acting Dihydropyridine Calcium Channel Blocker (CCB). This mechanism is unique because it works by preferentially relaxing the peripheral blood vessels, which effectively lowers blood pressure by reducing the resistance against which the heart must pump blood.


Q: Is Vasonorm used to treat heart conditions besides its main purpose?

A: Official indications list Vasonorm for high blood pressure and specific forms of chest pain (angina). Regulatory documents also state that it is approved to reduce the risk of certain cardiac events in patients with recently documented coronary artery disease (CAD) who do not have severe heart failure.


Q: Are there any common over-the-counter drugs that interact with Vasonorm?

A: Official labeling generally advises considering all non-prescription products. Any over-the-counter medicines, particularly those that may also affect blood pressure or involve the same metabolic pathways, could result in additive effects or altered exposure.


Q: Is Vasonorm known to cause issues with sleep?

A: Regulatory information lists somnolence, which means drowsiness or excessive sleepiness, as a common side effect. While this is related to the sleep-wake cycle, specific sleep disturbances like insomnia are generally considered less common based on the official adverse event profiles.


Q: Can Vasonorm cause skin rashes?

A: While a general skin rash is not listed as a common side effect, regulatory documents do report the occurrence of very rare but serious adverse reactions that involve the skin. These include severe dermatological reactions like Stevens-Johnson syndrome and angioedema, which are noted in the safety section.

How should Vasonorm be stored and disposed of?

Vasonorm tablets must be stored according to official regulatory requirements to maintain product stability and safety.

Required Storage Conditions

The medicine must be kept at controlled room temperature, generally defined as a range between 15 C and 30 C (59 F to 86 F). The product must be protected from moisture and should be kept in the original, tightly closed container.

Safety and Disposal

It is a mandatory safety instruction that Vasonorm must be stored safely out of the sight and reach of children.

For disposal, any unused or expired tablets must be discarded in accordance with local regulations and specific government guidance on pharmaceutical waste management. The product should not be disposed of in household trash or wastewater unless specifically instructed by a local drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasonorm found in:

A-Z Index: